Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
- Sponsor
- Rep. Hamadeh, Abraham J. [R-AZ-8]
- Committees
- Armed Services Committee (primary)
- Last action
- Jun 30, 2026
Bottom line
The bill mandates a DoD report evaluating specific clinical trial data on psilocybin for treatment-resistant PTSD in military populations, laying groundwork for potential future policy and research.
What it actually does
This bill directs the Assistant Secretary of Defense for Health Affairs to submit a report to Congress within 180 days. The report must assess the operational relevance, safety, dosing, and feasibility of data from a specific clinical trial (the 'Passage Trial' on psilocybin for PTSD) as it applies to servicemembers and veterans. It also requires an assessment of legal and regulatory pathways for expanded access to investigational Schedule I substances and considerations for continuity of care.
Proponents argue
Proponents argue that existing PTSD treatments are not effective for all servicemembers and veterans, leading to chronic impairment, substance misuse, and suicidality. They contend that rigorous research into emerging therapies, such as psilocybin-assisted therapy, is crucial to address these gaps and improve force health protection, medical readiness, and suicide prevention efforts. The bill provides a necessary step for the DoD to formally evaluate promising investigational treatments.
Opponents contend
Critics might express concerns about the safety and efficacy of investigational Schedule I substances, even in controlled clinical settings, and the potential risks associated with their integration into military healthcare systems. They may also argue that focusing on specific, potentially controversial treatments could divert resources or attention from established therapies or other mental health initiatives. Some may also raise concerns about the practicalities and ethical implications of administering such substances within a military context.
The bill text is short and relatively easy to read, allowing ample time for evaluation.
Section 2(b)
Mandate for Report on Emerging Treatment Options
This provision directs the Assistant Secretary of Defense for Health Affairs to submit a report to the congressional defense committees within 180 days of the bill's enactment. The report must focus on the operational relevance, safety, dosing, and feasibility of data from a specific clinical trial related to treatment-resistant post-traumatic stress disorder (PTSD) as it applies to members of the Armed Forces, including those transitioning to civilian life.
Supporters argue
Supporters argue that this report is a vital first step for the DoD to formally acknowledge and evaluate cutting-edge research into treatment-resistant PTSD, which could lead to better outcomes for servicemembers and veterans. It ensures that Congress is informed about potential new therapies.
Critics contend
No specific opposition is typically raised against a mandate for a report, as it is an informational gathering exercise. However, some might argue that the focus on a specific type of investigational treatment could be seen as premature or overly prescriptive.
Tradeoffs
The primary tension is between the urgency of finding new treatments for severe PTSD and the cautious, evidence-based approach required for introducing novel therapies, especially those involving controlled substances, into military healthcare.
Section 2(c)
Required Elements of the Report
This section details the specific information that must be included in the report. Key elements include a summary and analysis of safety, dosing, and adverse event data from the 'covered clinical trial' (a psilocybin study), an assessment of implications for force health protection and suicide prevention, a description of legal and regulatory requirements for expanded access to investigational Schedule I substances, and an assessment of continuity of care for transitioning servicemembers. It also requires an assessment of resources needed for potential pilot activities.
The bill explicitly identifies the 'covered clinical trial' as 'An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD'. This specifies that the report is focused on psilocybin-assisted therapy.
Section 2(a)(5) and Section 2(f)(2)
Why it matters:This level of detail is standard for legislative findings and definitions, providing specific context for the broader mandate. It's not necessarily evasive but requires careful reading to grasp the precise focus.
Case for: Proponents argue that explicitly naming the substance and trial provides clarity and ensures the DoD's report is directly relevant to specific ongoing research, preventing a generic or unfocused assessment. It acknowledges the specific advancements being made in this area.
Case against: Critics might suggest that by explicitly naming psilocybin, the bill could be perceived as endorsing or prioritizing a specific investigational treatment over others, potentially influencing the objectivity of the DoD's assessment or creating a precedent for similar legislative directives on other substances.
Estimated impact: This specificity directs the DoD's focus to a particular class of psychedelic-assisted therapies, potentially accelerating the evaluation and integration of such treatments for military personnel.
The bill mandates an assessment of the 'Federal Right to Try Act' (21 U.S.C. 360bbb-0a) and Executive Order No. 14401 ('Accelerating Medical Treatments for Serious Mental Illness') regarding their applicability to treatment-resistant PTSD and associated comorbidities, including elevated suicide risk.
Section 2(a)(9) and Section 2(c)(4)
Why it matters:These are specific legal and executive policy frameworks that are highly relevant to accessing investigational treatments, especially for serious conditions where standard therapies have failed. Their inclusion ensures a comprehensive legal review.
Case for: Proponents argue that exploring the 'Right to Try' pathway and the Executive Order is crucial for patients with life-threatening conditions like severe PTSD, offering a potential avenue for access to promising treatments outside of traditional clinical trials when no other options exist.
Case against: Critics of 'Right to Try' laws generally argue that they may expose patients to unproven and potentially unsafe treatments without the robust oversight of clinical trials, and that the benefits are often overstated. They might contend that assessing this pathway for Schedule I substances adds further complexity and risk.
Estimated impact: This assessment could pave the way for servicemembers and veterans with treatment-resistant PTSD to access investigational psilocybin therapies under specific compassionate use or 'Right to Try' provisions, potentially expanding treatment options significantly.